Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
Chumsri
Saranya
S
Zhao
Merry
M
Garofalo
Michael
M
Burger
Angelika
A
Hamburger
Anne
A
Zhao
Frank
F
Rapoport
Aaron
A
D000368:Aged; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011494:Protein Kinases / Q000187:drug effects*; D016879:Salvage Therapy; D020123:Sirolimus / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus